Larry Bauer provides counsel to drug manufacturers on a wide range of regulatory topics including Rare Pediatric Disease Designation requests, Orphan Drug Designation requests, Fast Track and Breakthrough Therapy Designation requests, drug development regulatory strategy, preparing regulatory submissions, and drafting regulatory policies and procedures. Mr. Bauer has extensive experience in patient advocacy and has expertise in the planning and execution of Patient Focused Drug Development meetings.
Prior to his current position, Mr. Bauer worked at the NIH for 17 years, part of which time was devoted to working on research for Gaucher disease. This time was followed by a position at the FDA as a Regulatory Scientist in CDER’s Rare Diseases Program working on policy, education, and science related to rare disease drug development. He was part of the committees that developed numerous guidances related to expedited programs, rare diseases, Pre-IND Meetings, and natural history studies. He participated in numerous internal and sponsor meetings related to the development and review of novel rare disease drugs. He also serves on the National Organization for Rare Disorders (NORD) Advocacy Committee.